Roivant Sciences Ltd. (ROIV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ROIV Stock Price Chart Interactive Chart >
ROIV Price/Volume Stats
| Current price | $4.04 | 52-week high | $16.76 |
| Prev. close | $4.10 | 52-week low | $2.52 |
| Day low | $3.90 | Volume | 1,167,600 |
| Day high | $4.18 | Avg. volume | 442,769 |
| 50-day MA | $4.09 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 2.80B |
Roivant Sciences Ltd. (ROIV) Company Bio
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ROIV News From Around the Web
Below are the latest news stories about Roivant Sciences Ltd that investors may wish to consider to help them evaluate ROIV as an investment opportunity.
Roivant Sciences (ROIV) Receives a Buy from H.C. WainwrightIn a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $14.00. The company's shares closed last Monday at $7.20, close to its 52-week low of $5.80. According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 39.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $14.50 average price target. |
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business UpdateRoivant’s newly launched subsidiary, Hemavant, entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001, a potential first-in-class small molecule modulator of splicing factor 3B subunit 1 (SF3B1) for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromesDermavant has hired key commercial leadership positions in preparation for launch of tapinarof for psoriasis, subject to the FDA’s appr |
Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ETRoivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium and Cowen Healthcare Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live confe |
Roivant Sciences (ROIV) Presents At B. Riley Securities Virtual Oncology Conference - SlideshowThe following slide deck was published by Roivant Sciences Ltd. in conjunction with this event.... |
Roivant to Present at Upcoming Investor ConferencesBASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ETSVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET A live webcast of each presentation will be available under “Events & Presentations” on the Investors section of th |
ROIV Price Returns
| 1-mo | 9.49% |
| 3-mo | -35.77% |
| 6-mo | -39.06% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -59.92% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...